Details for New Drug Application (NDA): 022052
✉ Email this page to a colleague
The generic ingredient in ZYFLO CR is zileuton. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the zileuton profile page.
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 600MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | May 30, 2007 | TE: | RLD: | Yes |
Expired US Patents for NDA 022052
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chiesi | ZYFLO CR | zileuton | TABLET, EXTENDED RELEASE;ORAL | 022052-001 | May 30, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | ZYFLO CR | zileuton | TABLET, EXTENDED RELEASE;ORAL | 022052-001 | May 30, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Chiesi | ZYFLO CR | zileuton | TABLET, EXTENDED RELEASE;ORAL | 022052-001 | May 30, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription